is Its GLP-1 Drug Poised to Rival Ozempic?

$6.82 +0.20 (+3.02%) (As of 02:12 PM ET) 52-Week Range $2.09 ▼ $14.84 Price Target $18.80 Clinical-state biopharmaceutical company Altimmune Inc. NASDAQ: ALT focuses on developing peptide-based therapeutics for obesity and chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Their top candidate is a GLP-1/glucagon agonist called pemvidutide. It’s a dual receptor agonist like Eli Lilly &…

Read More

RXO Stock Soars on New Acquisition Deal

Shares of RXO Inc. NYSE: RXO are up more than 20% on the week, something investors probably didn’t see coming out of the ‘boring’ transportation sector. This sector is notorious for having a low beta, English for low volatility. RXO stock has a beta below 1.0, meaning the company’s stock price will move less than…

Read More

IBB Nears Resistance with Amgen, Vertex

The biotechnology sector, represented by the iShares Biotechnology ETF NASDAQ: IBB, has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market, making it one of the worst-performing sectors year-to-date. However, as the year’s second half begins, the IBB is trading just 3% away from its 52-week high…

Read More

Steel Dynamics Up 9.6% as Competitors Rust

$124.01 -0.41 (-0.33%) (As of 02:13 PM ET) 52-Week Range $95.53 ▼ $151.34 Dividend Yield 1.48% P/E Ratio 8.52 Price Target $133.57 While most steel producer stocks are trading down in 2024, Steel Dynamics Inc. NASDAQ: STLD is an exception. Its stock is trading up 9.1% year-to-date (YTD). The VanEck Steel ETF (NYSEARCA: SLX) is down…

Read More

Snowflake Stock Rallies on AI Spending Increase

Artificial intelligence (AI) data cloud provider Snowflake Inc. NYSE: SNOW has had a series of misfortunate events, ranging from an earnings miss to data breaches, that caused its stock to tumble to 52-week lows at $122.60 on June 25, 2024. However, the shares have been able to rally for four consecutive days following the low…

Read More